KETOCONAZOLE AND QUINIDINE, INHIBITORS OF CYP450, 3A4 AND 2D6, RESPECTIVELY, INHIBIT DONEPEZIL METABOLISM IN VITRO . WHETHER THERE IS A CLINICAL EFFECT OF THESE INHIBITORS IS NOT KNOWN. INDUCERS OF CYP 2D6 AND CYP 3A4 (E.G., PHENYTOIN, CARBAMAZEPINE, DEXAMETHASONE, RIFAMPIN, AND PHENOBARBITAL) COULD INCREASE THE RATE OF ELIMINATION OF DONECEPT.
ANTICHOLINERGICS: BECAUSE OF THEIR MECHANISM OF ACTION, CHOLINESTERASE INHIBITORS HAVE THE POTENTIAL TO INTERFERE WITH THE ACTIVITY OF ANTICHOLINERGIC MEDICATIONS.
USE WITH CHOLINOMIMETICS AND OTHER CHOLINESTERASE INHIBITORS: A SYNERGISTIC EFFECT MAY BE EXPECTED WHEN CHOLINESTERASE INHIBITORS ARE GIVEN CONCURRENTLY WITH SUCCINYLCHOLINE, SIMILAR NEUROMUSCULAR BLOCKING AGENTS OR CHOLINERGIC AGONISTS SUCH AS BETHANECHOL